Comparison of the Clinicopathological Characteristics and Prognosis of Esophageal Squamous Cell Carcinoma with Intramural Metastases and Multiple Primary Carcinomas

被引:1
作者
Cheng, Na [1 ]
Li, Weihua [1 ]
Wang, Bingzhi [1 ]
Li, Zhuo [1 ]
Yang, Zhaoyang [1 ]
Chen, Rongshan [1 ]
Xue, Liyan [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Pathol, Natl Clin Res Ctr Canc,Canc Hosp, 17 Panjiayuan, Beijing 100021, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Ctr Canc Precis Med, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
LYMPH-NODE METASTASES; PRIMARY TUMORS; EXPRESSION;
D O I
10.1007/s00268-022-06839-9
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background It is difficult to distinguish esophageal squamous cell carcinoma with intramural metastases (IM) from multiple primary oesophageal carcinoma (MPEC). Nevertheless, there are significant differences in their prognoses and treatments. Therefore, our study aims to clarify the clinicopathological and prognostic characteristics of these two entities and to provide clues for differential diagnosis. Methods We retrospectively analyzed 6304 patients who underwent esophagectomy without neoadjuvant therapy. The clinicopathological and prognostic features of patients with IM and MPEC were evaluated. P53 and Rb1 were detected by immunohistochemical (IHC) staining using a tissue microarray. Results Among the 6304 patients, 127 (2.0%) had IM, and 138 (2.2%) had MPEC. Patients with IM were more likely to have an advanced pT (p < 0.001), pN (p < 0.001), more lymphovascular invasion (p < 0.001) and neural invasion (p < 0.001). Additionally, patients with IM had an extremely poor prognosis compared to those with MPEC, with 5-year overall survival (OS) rates of 18.9% and 56.9%, respectively. Meanwhile, IM was found to be an independent poor prognostic indicator for OS and DFS. In the IM group, all patients showed consistent p53 expression in both primary and IM foci. Of note, Rb1 loss was found in 3 pairs of primary foci and metastases, along with p53 nonsense mutation. Conclusions Patients with IM had more risk factors and extremely worse prognosis than those with MPEC. It is essential to discriminate IM from MPEC when managing multifocal carcinomas. IHC staining of p53 and Rb1 may aid in differential diagnosis.
引用
收藏
页码:707 / 716
页数:10
相关论文
共 26 条
  • [1] Tissue microarray (TMA) technology:: miniaturized pathology archives for high-throughput in situ studies
    Bubendorf, L
    Nocito, A
    Moch, H
    Sauter, G
    [J]. JOURNAL OF PATHOLOGY, 2001, 195 (01) : 72 - 79
  • [2] P53 expression in squamous cell carcinomas of the supraglottic larynx and its lymph node metastases -: New results for an old question
    Cabanillas, Ruben
    Rodrigo, Juan Pablo
    Astudillo, Aurora
    Dominguez, Francisco
    Suarez, Carlus
    Chiara, Maria Dolores
    [J]. CANCER, 2007, 109 (09) : 1791 - 1798
  • [3] Chen CZ., 2012, CHINA CANC, V21, P66
  • [4] Clinical analysis of 117 cases with synchronous multiple primary esophageal squamous cell carcinomas
    Chen, Zhiqin
    Li, Sihan
    He, Zheng
    Li, Guang
    [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 (06) : 1356 - 1364
  • [5] Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non-Small Cell Lung Cancers
    Girard, Nicolas
    Ostrovnaya, Irina
    Lau, Christopher
    Park, Bernard
    Ladanyi, Marc
    Finley, David
    Deshpande, Charuhas
    Rusch, Valerie
    Orlow, Irene
    Travis, William D.
    Pao, William
    Begg, Colin B.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (16) : 5184 - 5190
  • [6] Japanese Classification of Esophageal Cancer, 11th Edition: part I
    Japan Esophageal Society
    [J]. ESOPHAGUS, 2017, 14 (01) : 1 - 36
  • [7] INTRAMURAL METASTASIS OF THORACIC ESOPHAGEAL-CARCINOMA
    KATO, H
    TACHIMORI, Y
    WATANABE, H
    ITABASHI, M
    HIROTA, T
    YAMAGUCHI, H
    ISHIKAWA, T
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (01) : 49 - 52
  • [8] Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial
    Khoury, Joseph D.
    Wang, Wei-Lien
    Prieto, Victor G.
    Medeiros, L. Jeffrey
    Kalhor, Neda
    Hameed, Meera
    Broaddus, Russell
    Hamilton, Stanley R.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (03) : 521 - 531
  • [9] Tissue microarrays for high-throughput molecular profiling of tumor specimens
    Kononen, J
    Bubendorf, L
    Kallioniemi, A
    Bärlund, M
    Schraml, P
    Leighton, S
    Torhorst, J
    Mihatsch, MJ
    Sauter, G
    Kallioniemi, OP
    [J]. NATURE MEDICINE, 1998, 4 (07) : 844 - 847
  • [10] KUWANO H, 1988, CANCER-AM CANCER SOC, V61, P1635, DOI 10.1002/1097-0142(19880415)61:8<1635::AID-CNCR2820610822>3.0.CO